Realize the power of ctmDNA research
Easily identify disease-specific ctmDNA - Broad genomic screening technology from disease-state tissues coupled with sophisticated machine learning quickly identifies targets of interest
Fast targeted ctmDNA assay development – Custom design of targeted ctmDNA assay quickly produces statistically powerful datasets
Easy lab implementation – Custom kits for both Illumina and Thermo Fisher Scientific NGS to run in your laboratory takes only 1 day from DNA to sequencer-ready library
ctmDNA is a novel analyte with many possibilities for cancer and other disease states. Contact us today for research collaboration partnership opportunities.
The Co-Founders of Singlera Genomics
Biography of Yuan (Gary) Gao Ph.D., Chairman and Co-Founder
Dr. Yuan Gao is an innovator of translational technologies for next generation sequencing, non-invasive prenatal testing (NIPT), DNA methylation sequencing, and digital information storage in DNA. He is also a founder and President of Med Data Quest, Inc., developing clinical natural language processing and machine learning tools to aid precision medicine. He has a Bachelor of Bioscience from Beijing University, a Ph.D. in Computer Science from the Memphis University, completed his post-doctoral training with George Church at Harvard University, and most recently was an Associate Professor at Johns Hopkins University.
Biography of Kun Zhang, Ph.D., Co-founder and Scientific Advisor
Dr. Zhang is recognized for multiple achievements including single-cell whole genome sequencing, targeted DNA methylation sequencing, somatic genomic instability in induced pluripotent stem cells, Microwell Displacement Amplification System (MIDAS), and methylation haplotyping technology for non-invasive detection of ctDNA. Dr. Zhang holds a Ph.D. in Human and Molecular Genetics from the University of Texas Houston, completed his post-doctoral training with George Church at Harvard Medical School, and has a B.S. in Biophysics from Fudan University. He currently is a Professor in the Dept of Bioengineering at UCSD.
Johny Zhang, M.B.A., Co-Founder, Chief Executive Officer
Johny Zhang was previously the Vice President/General Manager for Greater China Thermo Fisher Scientific Healthcare, where he was awarded the annual global CEO award for outstanding performance. During his tenure at Gene Company, Ltd, Mr. Zhang introduced numerous molecular diagnostic technologies into China, including Dako IHC, Abbott FISH, Qiagen Nucleic Acid Detection, and Affymatrix Gene Chip. Mr. Zhang co-founded and was COO of www.ebiotrade.com, the first Chinese universal life science website of its kind. Mr. Zhang received his MBA and B.S. in Biochemistry from Fudan University.
Biography of Qiang Liu, M.B.A., Co-Founder, Chief Operating Officer
Mr. Liu is experienced in the evaluation of and investment in the biological and pharmaceutical industries and capital operations. Mr. Liu previously worked at the investment banks JP Morgan, Bank of New York, and Canadian Imperial Bank of Commerce. Mr. Liu has also successfully helped multiple Chinese companies in the United States and Canada on initial public offerings. Mr. Liu received his MBA from York University, Master of Biological Engineering from University of New South Wales, and B.S. in Biochemistry from Jilin University.
Biography of Rui Liu, Ph.D., Co-Founder, Chief Technology Officer
Dr. Liu first demonstrated ultra-low input RNA sequencing and whole-genome bisulfite sequencing in germ cells with Dr. Yi Zhang at Harvard University. She then developed large-scale single-cell RNA sequencing technology for the NIH Single Cell Analysis Program (coordinating laboratories at UCSD, Scripps Inst. and Illumina Inc.) to systematically map single-neuron RNA expression. Dr. Liu received a Ph.D. in Genetics from the Univ of Pennsylvania and did her post-doctoral work with Dr. Kun Zhang at UCSD. She also has a Bachelor’s degree in Clinical Medicine from Peking University and a B.S. in Biophysics from Fudan University.
Prof. George Church: Harvard Medical School, elected member of NAS, NAE, AAAS
George Church, professor at Harvard & MIT, co-author of 490 papers, 130 patent publications & the book "Regenesis", developed methods used for the first genome sequence (1994) & million-fold cost reductions since (via NGS and nanopores), plus barcoding, DNA assembly from chips, genome editing, writing & recoding. He co-initiated the BRAIN Initiative (2011) & Genome Projects (1984, 2005) to provide & interpret the world's only open-access personal precision medicine datasets.
Prof. Jin Li, Vice President of Fudan University; elected member of Chinese Academy of Science
Dr. Jin Li received BS and MS at Fudan University in 1985 and 1987, respectively, and received a Ph.D. in Biomedical Sciences/Genetics at Houston Health Science Center of University of Texas in 1994, and between 1994 and 1996, he had post-doctoral training at Stanford University. In 1997, he was engaged by the School of Life Sciences of Fudan University as a part-time professor, and in 2005, he returned to China, and became a full-time professor of the School of Life Sciences, and from 2003 to 2008, he served as the dean of the School of Life Sciences. His main research areas include medical genetics and genetic epidemiology, human population genetics, and computational biology.
Prof. Zhou Honghao, Director of Institute of Pharmacology, Central South University; elected member of Chinese Academy of Engineering
Dr. Zhou Honghao graduated from the Medical Dept of the former Wuhan Medical College in 1962. In 1983, he went to the Medical Faculty of The University of Hong Kong for Clinical Pharmacology training, then worked as senior fellow at the Clinical Pharmacology Laboratory of Vanderbilt University in the United States. He returned to homeland to set up China’s first Institute of Pharmacogenetics in 1991. He was appointed director of Institute of Clinical Pharmacology of Central South University in February 2002 and in December 2005, he was elected as Academician of Chinese Academy of Engineering.
Professor Zhou Honghao is a pioneer and foregoer of pharmacogenetics and pharmacogenomics disciplines and founder of individualized medicine.
Prof. Cheng Liang, Professor of pathology at the Indiana University Medical School
Dr. Liang Cheng is Professor of Pathology and Urology at the Indiana University School of Medicine, Indianapolis, Indiana, USA. Currently, he is the Chief of the Genitourinary Pathology Service, Director of the Urologic Pathology Fellowship, and Director of Molecular Diagnostics and Molecular Pathology Laboratories. Dr. Cheng is board certified in Molecular Genetic Pathology and Anatomic and Clinical Pathology by the American Board of Pathology. Dr. Cheng graduated from Beijing Medical University. Dr. Cheng completed his pathology residency at Case Western Reserve University, Cleveland, Ohio and his fellowship at the Mayo Clinic, Rochester, Minnesota in 1998. Dr. Cheng has received numerous prestigious awards including the Stowell-Orbison Award from the United States and Canadian Academy of Pathology (USCAP) and the Koss Medal Award from the International Society of Urological Pathology (ISUP). In 2006, he was the Arthur Purdy Stout Prize recipient from the Arthur Purdy Stout Society of Surgical Pathologists.
Prof. Kun Zhang, Department of Bioengineering, University of California at San Diego
Dr. Zhang is recognized for multiple achievements including single-cell whole genome sequencing, targeted DNA methylation sequencing, somatic genomic instability in induced pluripotent stem cells, Microwell Displacement Amplification System (MIDAS), and methylation haplotyping technology for non-invasive detection of ctDNA. Dr. Zhang holds a Ph.D. in Human and Molecular Genetics from the University of Texas Houston, completed his post-doctoral training with George Church at Harvard Medical School, and has a B.S. in Biophysics from Fudan University. He currently is a Professor in the Dept of Bioengineering at UCSD.
Prof. Yuan (Gary) Gao, Department of Biomedical Engineering, Johns Hopkins University
Dr. Yuan Gao is an innovator of translational technologies for next generation sequencing, non-invasive prenatal testing (NIPT), DNA methylation sequencing, and digital information storage in DNA. He is also a founder and President of Med Data Quest, Inc., developing clinical natural language processing and machine learning tools to aid precision medicine. He has a Bachelor of Bioscience from Beijing University, a Ph.D. in Computer Science from the Memphis University, completed his post-doctoral training with George Church at Harvard University, and most recently was an Associate Professor at Johns Hopkins University.
Scientific Advisory Board
Discover The Future
At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future.
